Cardiology - European Medical Journal

Continue

Cardiology

Filter
Microbiol & Infect Dis CP
8 Mins
1 Feb 2021

Editor's Pick: The Correlation Between Stroke and Coronavirus Disease (COVID-19): Where is the Evidence?

Stroke is a cerebrovascular disease, whereby blockage or rupture of a cerebral artery results in cerebral infarction or haemorrhage, respectively…
4 Mins
29 Jan 2021

Mavacamten Positively Impacts Underlying Hypertrophic Cardiomyopathy Mechanisms as Well as Cardiac Structure and Function: Findings from the EXPLORER-HCM Study

Obstructive hypertrophic cardiomyopathy (HCM) is a progressive myocardial disorder characterised by dynamic left ventricular outflow tract (LVOT)…
5 Mins
25 Jan 2021

‘Dry’ Pericarditis with Rapid Progression to Tamponade as a Feature of COVID-19

A 63-year-old female presented to hospital with severe, central, sharp chest pain, exacerbated by deep inspiration and upon lying back. She denied cough, fever, or other systemic symptoms…
EMJ Cardiology 8 [Supplement 4] 2020 Feature Image
8 Mins
22 Dec 2020

Long-Term Benefits of a Holistic Approach on Dyslipidaemia Management

Prof Banach explained that current lipid-lowering therapy (LLT) with statins, ezetimibe, and proprotein convertase subtilisin/kexin Type 9 inhibitors…
7 Mins
14 Dec 2020

Looking PHorward to Improving Long-Term Outcomes in Pulmonary Arterial Hypertension

PH encompasses a heterogeneous group of conditions, including PAH (Group 1), PH due to LHD (Group 2), PH due to lung diseases and/or hypoxia…
5 Mins
10 Dec 2020

Surrounding Advanced Heart Failure: The Role of the Latest Left Ventricular Assist Devices

Advanced stage heart failure accounts for 1-10% of the overall heart failure population and the prevalence is increasing, in part because of…
8 Mins
20 Oct 2020

Therapeutic Advances in Patients with Heart Failure with Reduced Ejection Fraction Who Have Had a Previous Worsening Heart Failure Event

European and USA treatment guidelines are aligned in their standard recommendation of therapies for symptomatic HFrEF. First-line…
EMJ Cardiology 8.1 2020 Feature Image
8 Mins
20 Oct 2020

New Insights into Icosapent Ethyl for Patients with Residual Cardiovascular Risk

REDUCE-IT was a Phase IIIb, double-blind, placebo-controlled trial that randomised 8,179 patients to receive icosapent ethyl (4 g/day) or placebo…